CS-807 was administered to 22 patients with respiratory tract infection (RTI)(acute pharyngitis 1, acute bronchitis 10, pneumonia 1, pneumonia and pyothorax 1, bronchial asthma and infection 1) and ...urinary tract infection (UTI)(chronic cystitis 2, acute pyelonephritis 3). CS-807 at 200mg or 100mg was administered twice daily. Overall efficacy was evaluated as 77.3%, being 76.5% and 80.0% for RTI and UTI. Side-effects were: diarrhea in one case. Laboratory abnormalities were: slight eosinophilia, slight elevations of GOT and GPT, and slight increase in BUN and serum creatinine in one patient each.
BAY o 9867 (Ciprofloxacin) was studied about its clinical efficacy, side effects and laboratory values with 23 cases of infectious diseases: 7 cases with acute bronchitis, 2 cases with chronic ...bronchitis, 3 cases with pneumonia, 2 case with acute cystitis, 2 cases with chronic cystitis, 7 cases with acute pyelitis. Twelve cases were treated with 300mg (3×) of BAY o 9867 a day and other cases with 600mg (3×) a day. The duration of the treatment ranged from 3 to 18 days. The cases studied showed the following clinical efficacy: 7 cases of acute bronchitis; 2 excellent, 4 good, 1 fair 2 cases of chronic bronchitis; 1 fair, 1 poor 3 cases of pneumonia; 2 excellent, 1 good 2 cases of acute cystitis; 1 good (excluded 1 case) 2 cases of chronic cystitis; 2 good 7 cases of acute pyelitis; 2 excellent, 1 good (excluded 4 cases) The whole efficacy rate was 83.3%. As the pathogen in RTI, K. pneumoniae was identified each one case of acute bronchitis and chronic bronchitis.In UTI, mono infecqions were found to occur due to E. coli in 3 cases, due to S. pyogenes, P. vulgaris and P. mirabilis each in one case. These pathogens were eliminated following the treatment of BAY o 9867. As to side effects, fatigue appeared 2 days after the administrawlon in one case. The laboratory test recognized a slight elevation of BUN in one case.
BRL 28500, a formulation of ticarcillin (TIPC, 15 parts) and clavulanic acid (CVA, 1 part) was evaluated for clinical efficacy in 20 patients suffering from pneumonia (8), chronic bronchitis (2), ...acute cystitis (1), chronic cystitis (4), acute pyelitis (3) and chronic pyelitis (2). The clinical response was excellent in 7 patients, good in 12 and poor in 1. All strains of bacteria were eradicated following the administration of BRL 28500 including 3 that were considered ticarcillin-resistant. Against 2 of these resistant strains the MIC of BRL 28500 was determined. One strain (K. Oxytoca) was sensitive to BRL 28500 although the other strain (P.aeruginosa) appeared resistant. There were no side effects. Laboratory abnormalities were limited to a slight elevation of GOT, GPT, LDH and γ-GTP in 1 case.
To evaluate the clinical efficacy of DL-8280, the treatment was made with the drug in 45 patients including 7 with pneumonia, 2 with acute bronchitis, 6 with chronic bronchitis, 4 with acute purulent ...tonsillitis, 7 with acute cystitis, 8 with chronic cystitis, 5 with acute pyelitis, 1 with chronic pyelitis, 2 with acute cholecystitis, 1 with chronic cholangitis and 2 with acute enteritis. Responses were excellent in 20 patients, good in 23 and fair in 2. The efficacy rate of DL-8280 was 95.6%. As side effect, dizziness and photophobia were observed in 1 out of 47 patients. Six patients showed the following abnormal laboratory findings after treatment; temporal elevation of GOT, GPT, Al-P and γ-GTP in 1 case, temporal elevation of BUN in 3 cases and temporal eosinophilia in 2 cases.
Ceftriaxone (CTRX, Ro 13-9904) was studied about its clinical efficacy, side effects and laboratory values with 20 cases of infectious diseases: 10 cases with pneumonia, 1 with acute bronchitis, 2 ...with acute cystitis, 2 with chronic cystitis, 2 with acute pyelonephritis, 2 with chronic pyelonephritis and 1 with chronic cholangitis. 16 cases received CTRX as an one-hour drip injection and the other 4 as an intravenous injection. 4 cases were treated with 1 g dose once a day, 14 cases with 1 g twice a day and the remaining 2 with 0.5 g twice a day. The duration of treatment ranged from 5 to 15 days. As the pathogen, S. aureus and S. pn. were identified each in one case of pneumonia. S. pn. was detected also in a case of acute bronchitis. In urinary tract infections, monoinfections were found to occur due to E. coli in 2 cases, due to C. freundii, P. cepacia and P. maltophilia each in one case, and 3 cases had mixed infections due to E. coli associated with γ-Strep. sp., P. aeruginosa associated with S. faecalis and E. coli associated with Aeromonas hydrophilia, respectively. The cases studied showed the following clinical efficacy: 10 cases of pneumonia; 1 excellent, 8 good, 1 fair. 1 case of bronchitis; good. 2 cases of acute cystitis and 2 of chronic cystitis; 2 excellent, 2 good. 2 cases of acute pyelonephritis; 1 good, 1 poor. 2 cases of chronic pyelonephritis; 1 excellent, 1 good. 1 case of chronic cholangitis; good. As a whole, excellent responses were observed in 4 cases, good in 14, fair in 1 and poor in 1, and the efficacy rate was 90%. As to side effects, 37.8°C of fever appeared 13 days after administration in one case, but it recovered by discontinuation of treatment. The laboratory test recognized eosinophilia (1380) 10 days after administration of this drug and observed a slight elevation of S-GOT in one case.
